Famous drug company Ellie Lily has launched weekly injections, monjarso (Tirgptide) for obesity and type 2 diabetes in India. The company has received permission from India’s Central Drug Standards Control Organization (CDSCO) to launch this drug in India. Although the company has not yet discussed the price of Monjaro in India, there is a huge demand for Monjaro in the US and Europe. Its launch in India is part of Lily’s widespread strategy to increase access to new medical practices in emerging markets.
Preparations to ensure affordable availability of medicines
According to reports, the company is working with healthcare providers, insurance companies and policy makers to ensure affordable availability of medicine. Monzaro activates both GIP and GLP-1 hormone receptors, and reflects significant weight loss and blood sugar control in clinical trials. GLP-1, or glucagon-like peptide-1, is a hormone produced in the human body that is important in controlling blood sugar levels and appetite.
Obesity and diabetes are the major public health challenges
Lily India President and General Manager Vinslo Tucker said that the double burden of obesity and type 2 diabetes is rapidly emerging as a major public health challenge in India. The company is “committed to cooperation with the government and business to improve prevention and management.” According to the news, in an American study of Tirzepetides in obese people, known as Surmount-1 clinical trial, monjarso resulted in a result of 21.8 kg on the highest dose (15 mg) in 72 weeks and 15.4 kg on lowest dose (5 mg).
Additionally, one in three patients lost more than 25% weight of his body, which is much higher than 1.5% seen in the Placebo group. Dr., Senior Medical Director, Lily India. Manish Mistry said that Monjaro in India will “provide a new approach to metabolic health management.”
